CA2347330A1 - Liquid injectable formulation of disodium pamidronate - Google Patents

Liquid injectable formulation of disodium pamidronate Download PDF

Info

Publication number
CA2347330A1
CA2347330A1 CA 2347330 CA2347330A CA2347330A1 CA 2347330 A1 CA2347330 A1 CA 2347330A1 CA 2347330 CA2347330 CA 2347330 CA 2347330 A CA2347330 A CA 2347330A CA 2347330 A1 CA2347330 A1 CA 2347330A1
Authority
CA
Canada
Prior art keywords
solution
manufacture
injectable formulation
physiologically acceptable
ready
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2347330
Other languages
French (fr)
Other versions
CA2347330C (en
Inventor
Sam Hahn
Dennis Szymanski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaceutical Partners of Canada Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4169021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2347330(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to CA002347330A priority Critical patent/CA2347330C/en
Priority to CA002372450A priority patent/CA2372450A1/en
Publication of CA2347330A1 publication Critical patent/CA2347330A1/en
Priority to PCT/CA2001/001617 priority patent/WO2002089768A1/en
Application granted granted Critical
Publication of CA2347330C publication Critical patent/CA2347330C/en
Priority to US10/346,924 priority patent/US20040147486A1/en
Priority to US11/036,295 priority patent/US20050182030A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

The present invention relates to an improved injectable ready to use preparation of pamidronate salts, methods for its manufacture and uses of the solution of the invention in the manufacture of pharmaceutical compositions for the treatment of diseases selected from the group of tumour-induced hypercalcaemia, Paget's disease, osteoporosis, bone metastases, or breast cancer. The ready to use solution comprises a physiologically acceptable alkaline salt which is water soluble and a physiologically acceptable aqueous solvent having a concentration of between 0.1 and 100 mg/mL which has not been reconstituted from a lyophilizate, wherein the solution is provided in a sealed non-reactive container.
CA002347330A 2001-05-10 2001-05-10 Liquid injectable formulation of disodium pamidronate Expired - Fee Related CA2347330C (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002347330A CA2347330C (en) 2001-05-10 2001-05-10 Liquid injectable formulation of disodium pamidronate
CA002372450A CA2372450A1 (en) 2001-05-10 2001-05-10 Liquid injectable formulation of disodium pamidronate
PCT/CA2001/001617 WO2002089768A1 (en) 2001-05-10 2001-11-15 Liquid injectable formulation of disodium pamidronate
US10/346,924 US20040147486A1 (en) 2001-05-10 2003-01-17 Liquid injectable formulation of disodium pamidronate
US11/036,295 US20050182030A1 (en) 2001-05-10 2005-01-14 Liquid injectable formulation of disodium pamidronate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002347330A CA2347330C (en) 2001-05-10 2001-05-10 Liquid injectable formulation of disodium pamidronate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002372450A Division CA2372450A1 (en) 2001-05-10 2001-05-10 Liquid injectable formulation of disodium pamidronate

Publications (2)

Publication Number Publication Date
CA2347330A1 true CA2347330A1 (en) 2001-09-19
CA2347330C CA2347330C (en) 2002-03-12

Family

ID=4169021

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002372450A Abandoned CA2372450A1 (en) 2001-05-10 2001-05-10 Liquid injectable formulation of disodium pamidronate
CA002347330A Expired - Fee Related CA2347330C (en) 2001-05-10 2001-05-10 Liquid injectable formulation of disodium pamidronate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002372450A Abandoned CA2372450A1 (en) 2001-05-10 2001-05-10 Liquid injectable formulation of disodium pamidronate

Country Status (3)

Country Link
US (2) US20040147486A1 (en)
CA (2) CA2372450A1 (en)
WO (1) WO2002089768A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
JP5243789B2 (en) * 2004-03-15 2013-07-24 シティ・オブ・ホープ Methods and compositions for specific inhibition of gene expression by double stranded RNA
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2006100687A1 (en) * 2005-03-24 2006-09-28 Dabur Pharma Ltd. Disodium pamidronate aqueous formulation
US20070166187A1 (en) * 2006-01-18 2007-07-19 Song Jing F Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers
CA2871061C (en) * 2012-04-27 2017-06-20 Sun Pharmaceutical Industries Ltd Ready to be infused gemcitabine solution

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (en) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Use of 3-amino-1-hydroxypropane-1, 1-diphosphonic acid or its water-soluble salts for influencing calcium metabolic disorders in the human or animal body
DE2943498C2 (en) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Process for the preparation of 3-amino-1-hydroxypropane-1,1-diphosphonic acid
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
US4439194A (en) * 1981-09-08 1984-03-27 Merck & Co., Inc. Water and drug delivery system for suppository use
US4513891A (en) * 1982-04-15 1985-04-30 Sterling Drug Inc. Spray dispensing container and valve therefor
DE3225469A1 (en) * 1982-07-05 1984-01-05 Schering AG, 1000 Berlin und 4709 Bergkamen DIPHOSPHONIC ACID DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US4797388A (en) * 1984-05-21 1989-01-10 Cetus Corporation Pharmaceutical compositions with galactitol as carrier
DE3428524A1 (en) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
IT1187828B (en) * 1985-05-24 1987-12-23 Gentili Ist Spa PHARMACEUTICAL COMPOSITION BASED ON DIPHOSPHONATES FOR THE TREATMENT OF ARETROSIS
US4902679A (en) * 1985-12-13 1990-02-20 Norwich Eaton Pharmaceuticals, Inc. Methods of treating diseases with certain geminal diphosphonates
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5159108A (en) * 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
DE69204007T2 (en) * 1991-10-11 1996-03-21 Squibb & Sons Inc Use of farnesyl-protein transferase inhibitors for the manufacture of a medicament for blocking neoplastic transformations of cells caused by Ras oncogenes.
EP0618805A1 (en) * 1991-12-17 1994-10-12 PROCTER & GAMBLE PHARMACEUTICALS, INC. Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
EP0550385A1 (en) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
TW237386B (en) * 1992-04-15 1995-01-01 Ciba Geigy
ATE179329T1 (en) * 1992-06-30 1999-05-15 Procter & Gamble Pharma MEDICINAL PRODUCTS FOR THE TREATMENT OF ARTHRITIS THAT CONTAIN PHOSPHONATES AND NSAIDS
DE4228552A1 (en) * 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Drugs containing diphosphonic acids and their salts
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FR2703590B1 (en) * 1993-04-05 1995-06-30 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR PROMOTING BONE REPAIR.
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
AU684878B2 (en) * 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
DE4416928C1 (en) * 1994-05-13 1995-08-17 Lohmann Gmbh & Co Kg Medical adhesive material for sweat-resistant dressings etc.
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
JP3411690B2 (en) * 1994-09-21 2003-06-03 帝人株式会社 Alendronate sodium preparation for topical administration
JP3576608B2 (en) * 1994-11-15 2004-10-13 日東電工株式会社 Patches and patch preparations
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
AU7213196A (en) * 1995-09-29 1997-04-28 Ciba-Geigy Ag Method of treating the navicular disease in horses
US5723151A (en) * 1995-11-06 1998-03-03 Eastman Chemical Company Cellulose acetate phthalate enteric coating compositions
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US20020035058A1 (en) * 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US6376477B2 (en) * 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
UA59384C2 (en) * 1996-12-20 2003-09-15 Пфайзер, Інк. Preventing bone mass loss and recovery thereof by means of prostaglandin agonists
SE9702401D0 (en) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ATE356139T1 (en) * 1997-06-25 2007-03-15 Pfizer DIPEPTIDE DERIVATIVES FOR PROMOTING GROWTH HORMONE SECRETION
UA53716C2 (en) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. A substituted dipeptide tartaric salt as an agent stimulating the growth hormone secretion
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
US20010025028A1 (en) * 1998-03-13 2001-09-27 Merck & Co., Inc. Methods of inhibiting bone resorption
US6750340B2 (en) * 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
FR2784031B1 (en) * 1998-10-02 2002-02-01 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF LAMPS
US6414006B1 (en) * 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
US20010006980A1 (en) * 1998-10-15 2001-07-05 Harada Shun-Ichi Methods for stimulating bone formation
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
DE69907258T2 (en) * 1998-12-10 2003-11-06 Aesgen Inc METHOD FOR PRODUCING DINATRIUM PAMIDRONATE
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
IL142515A0 (en) * 1999-12-20 2002-03-10 Merck & Co Inc Pharmaceutical kit
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
EP1252162B1 (en) * 2000-01-20 2012-07-25 Merck Sharp & Dohme Corp. Alpha v integrin receptor antagonists
US6562974B2 (en) * 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
JP2001253827A (en) * 2000-02-15 2001-09-18 Pfizer Prod Inc Composition and method for treating osteoporosis
AU2001236713A1 (en) * 2000-02-17 2001-08-27 Genzyme Corporation Methods for treatment of lysosomal storage diseases
AUPR018900A0 (en) * 2000-09-18 2000-10-12 Fh Faulding Pty Limited Pamidronate solution
US20020004218A1 (en) * 2000-03-31 2002-01-10 Rodan Gideon A. Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
BR0110316A (en) * 2000-04-07 2005-01-18 Regents For The University Of Unique Zwitterionic Phospholipid and Bisphosphonate Compositions and Use of the Compositions as Bisphosphate Delivery Systems with Reduced Gly Toxicity
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20020019373A1 (en) * 2000-07-06 2002-02-14 American Home Products Corporation Combinations of bisphosphonates and estrogenic agents
US20020028792A1 (en) * 2000-07-06 2002-03-07 American Home Products Corporation Combinations of bisphosphonates, estrogens and estrogenic agents
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
DE60134251D1 (en) * 2000-09-18 2008-07-10 Sanos Bioscience As USE OF GLP-2 PEPTIDES
DE20106394U1 (en) * 2001-04-11 2001-08-09 Helm Pharmaceuticals Gmbh Pharmaceutical preparation
RU2003134700A (en) * 2001-05-02 2005-03-20 Сикор Инк. (Us) DISATRIUM PAMIDRONATE FOR INJECTION

Also Published As

Publication number Publication date
CA2372450A1 (en) 2001-09-19
WO2002089768A1 (en) 2002-11-14
US20040147486A1 (en) 2004-07-29
CA2347330C (en) 2002-03-12
US20050182030A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
HUP0204114A2 (en) Pharmaceutical parenteral composition containing biphosphonate
JP3062001B2 (en) Use of bisphosphonic acid derivatives for the preparation of a pharmaceutical composition intended to promote bone repair and the corresponding pharmaceutical composition
RU96123917A (en) ORAL LIQUID COMPOSITIONS CONTAINING ALENDRONATE
CA2190148C (en) Oral liquid alendronate formulations
US8263136B2 (en) Low dose colonic cleansing system
NZ332314A (en) Oral pharmaceutical preparation containing ibandronate or salts thereof in the form of an inner section containing the active ingredient surrounded by a coating free of the active ingredient
JP2004508410A5 (en)
MXPA96005660A (en) Oral liquid formulations of alendron
RU2007136046A (en) MEDICINAL FORM OF RIZEDRONATE
JP2002529490A (en) Methods for inhibiting tooth-absorbable lesions
JP2004075690A (en) Alendronate composition for intravenous infusion
JPH06505501A (en) How to treat osteoporosis
WO2006066067A2 (en) Formulations of bisphosphonate drugs with improved bioavailability
WO2007055885A3 (en) Pharmaceutical gallium compositions and methods
PL316987A1 (en) Biphosphonic acids containing preparation obtained by a wet granulation process
JP2003504384A (en) Potassium calcium citrate composition and production method
CA2347330A1 (en) Liquid injectable formulation of disodium pamidronate
CA2409930A1 (en) Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases
JPH08500830A (en) Pharmaceuticals containing diphosphonic acid and its salts
RU2004105144A (en) COMBINATIONS INCLUDING EPOTHYLONS AND THEIR PHARMACEUTICAL USE
CA2431515C (en) Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition, and use thereof
CZ322199A3 (en) Stable solid preparation containing vitamin D3 and tricalcium phosphate
JPH0415235B2 (en)
GB2153225A (en) Effervescent preparations containing diphosphonates
EP1651191B1 (en) Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed